Roche announced the launch of Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody to identify PRAME protein expression in tissue samples from patients with suspected melanoma.
Because the PRAME (PReferentially expressed Antigen in MElanoma) protein is expressed in most melanomas, the PRAME (EPR20330) Antibody is used as an aid to differentiate between benign and malignant lesions to help improve diagnostic decisions. If PRAME expression is detected, this suggests that the lesion is malignant.
The first test that is used to evaluate a potential melanocytic lesion is a hematoxylin and eosin (H&E) stain of the patient’s tissue sample. However, not all melanomas are easily diagnosed using H&E alone. Studies suggest that the detection of PRAME expression by immunohistochemistry (IHC) complements findings from routinely used tests and enables more informed clinical decisions and improved patient outcomes. In particularly challenging cases, the use of PRAME IHC may highlight abnormal cells expressing the PRAME protein and provide more confidence in the diagnosis of melanoma.
More information about PRAME will be presented at the International Academy of Pathology 2022 World Congress in Sydney, Australia, on October 14, 2022, in a session titled “The diagnostic approach to melanocytic lesions.”
